🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 4 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 13/11/1992 | 5,75 | 6,13 | 5,63 | 6,00 | +4,35% | 8,70% | 69.600 |
| 12/11/1992 | 5,38 | 5,75 | 5,38 | 5,75 | +2,22% | 6,98% | 189.200 |
| 11/11/1992 | 5,63 | 5,63 | 5,38 | 5,63 | +2,27% | 4,44% | 14.800 |
| 10/11/1992 | 5,75 | 5,75 | 5,50 | 5,50 | -2,22% | 4,35% | 251.200 |
| 09/11/1992 | 4,88 | 5,63 | 4,88 | 5,63 | +15,38% | 15,38% | 90.800 |
| 06/11/1992 | 5,13 | 5,13 | 4,88 | 4,88 | -2,50% | 4,88% | 6.800 |
| 05/11/1992 | 5,00 | 5,13 | 4,88 | 5,00 | +0,00% | 5,00% | 39.600 |
| 04/11/1992 | 5,00 | 5,00 | 4,75 | 5,00 | +5,26% | 5,00% | 29.800 |
| 03/11/1992 | 4,75 | 5,00 | 4,63 | 4,75 | +0,00% | 7,89% | 71.800 |
| 02/11/1992 | 4,88 | 4,88 | 4,50 | 4,75 | +5,56% | 7,69% | 58.400 |
| 30/10/1992 | 4,88 | 4,88 | 4,50 | 4,50 | -2,70% | 7,69% | 21.800 |
| 29/10/1992 | 4,63 | 4,88 | 4,63 | 4,63 | +0,00% | 5,41% | 9.800 |
| 28/10/1992 | 4,63 | 4,88 | 4,63 | 4,63 | -5,13% | 5,41% | 6.400 |
| 27/10/1992 | 4,63 | 4,88 | 4,63 | 4,88 | +0,00% | 5,41% | 19.600 |
| 26/10/1992 | 4,63 | 5,00 | 4,63 | 4,88 | -2,50% | 8,11% | 20.400 |
| 23/10/1992 | 5,00 | 5,00 | 4,75 | 5,00 | +8,11% | 5,00% | 13.800 |
| 22/10/1992 | 4,75 | 5,00 | 4,63 | 4,63 | -7,50% | 7,89% | 35.000 |
| 21/10/1992 | 5,00 | 5,00 | 4,75 | 5,00 | +0,00% | 5,00% | 4.200 |
| 20/10/1992 | 4,63 | 5,00 | 4,63 | 5,00 | +0,00% | 8,11% | 6.400 |
| 19/10/1992 | 4,88 | 5,00 | 4,63 | 5,00 | +8,11% | 7,69% | 5.200 |
| 16/10/1992 | 4,63 | 4,88 | 4,63 | 4,63 | -2,63% | 5,41% | 5.400 |
| 15/10/1992 | 4,63 | 4,88 | 4,63 | 4,75 | -2,56% | 5,41% | 5.200 |
| 14/10/1992 | 4,63 | 4,88 | 4,63 | 4,88 | +0,00% | 5,41% | 8.400 |
| 13/10/1992 | 4,63 | 4,88 | 4,63 | 4,88 | +2,63% | 5,41% | 7.000 |
| 12/10/1992 | 4,63 | 4,75 | 4,63 | 4,75 | +2,70% | 2,70% | 1.600 |
| 09/10/1992 | 4,88 | 4,88 | 4,63 | 4,63 | -3,90% | 5,13% | 8.000 |
| 08/10/1992 | 4,88 | 4,88 | 4,69 | 4,81 | -1,28% | 3,85% | 6.000 |
| 07/10/1992 | 5,00 | 5,00 | 4,63 | 4,88 | +0,00% | 7,50% | 20.200 |
| 06/10/1992 | 4,88 | 5,13 | 4,75 | 4,88 | +1,30% | 7,69% | 46.600 |
| 05/10/1992 | 5,00 | 5,13 | 4,75 | 4,81 | -3,75% | 7,50% | 51.800 |